Aortic dissection other diagnostic studies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[ESC guidelines classification scheme#Classification of Recommendations|Class I]] | | colspan="1" style="text-align:center; background:LightGreen"|[[ESC guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
|bgcolor="LightGreen" |<nowiki>"</nowiki>It is recommended to investigate first-degree relatives (siblings and parents) of a subject with TAAD to identify a familial form in which relatives all have a 50% chance of carrying the family mutation/disease.''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |bgcolor="LightGreen" |<nowiki>"</nowiki>It is recommended to investigate first-degree relatives (siblings and parents) of a subject with TAAD to identify a familial form in which relatives all have a 50% chance of carrying the family [[mutation]]/disease.''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |- | ||
|bgcolor="LightGreen" |<nowiki>"</nowiki>Once a familial form of TAAD is highly suspected, it is recommended to refer the patient to a geneticist for family investigation and molecular testing.''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |bgcolor="LightGreen" |<nowiki>"</nowiki>Once a familial form of TAAD is highly suspected, it is recommended to refer the [[patient]] to a geneticist for family investigation and [[molecular testing]].''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|- | |- | ||
|bgcolor="LightGreen" |<nowiki>"</nowiki>Variability of age of onset warrants screening every 5 years of ‘healthy’ at-risk relatives until diagnosis (clinical or molecular) is established or ruled out.''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |bgcolor="LightGreen" |<nowiki>"</nowiki>Variability of age of onset warrants [[screening]] every 5 years of ‘healthy’ at-risk relatives until [[diagnosis]] (clinical or molecular) is established or ruled out.''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|} | |} | ||
{|class="wikitable" | {|class="wikitable" | ||
| Line 20: | Line 20: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ESC guidelines classification scheme#Classification of Recommendations|Class IIa]] | | colspan="1" style="text-align:center; background:LemonChiffon"|[[ESC guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
|bgcolor="LemonChiffon" |<nowiki>"</nowiki>In familial non-syndromic TAAD, screening for aneurysm should be considered, not only in the thoracic aorta, but also throughout the arterial tree (including cerebral arteries).''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |bgcolor="LemonChiffon" |<nowiki>"</nowiki>In familial non-syndromic TAAD, [[screening]] for [[aneurysm]] should be considered, not only in the [[thoracic aorta]], but also throughout the arterial tree (including [[cerebral arteries]]).''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|} | |} | ||
==References== | ==References== | ||
Latest revision as of 17:14, 30 December 2019
|
Aortic dissection Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenarios |
|
Case Studies |
|
|
Overview
Other Diagnostic Studies
2014 ESC Guidelines on the Diagnosis and Treatment of Aortic Diseases (DO NOT EDIT)[1]
Genetic Testing in Aortic Dissection (DO NOT EDIT)[1]
| Class I |
| "It is recommended to investigate first-degree relatives (siblings and parents) of a subject with TAAD to identify a familial form in which relatives all have a 50% chance of carrying the family mutation/disease.(Level of Evidence: B)" |
| "Once a familial form of TAAD is highly suspected, it is recommended to refer the patient to a geneticist for family investigation and molecular testing.(Level of Evidence: C)" |
| "Variability of age of onset warrants screening every 5 years of ‘healthy’ at-risk relatives until diagnosis (clinical or molecular) is established or ruled out.(Level of Evidence: C)" |
| Class IIa |
| "In familial non-syndromic TAAD, screening for aneurysm should be considered, not only in the thoracic aorta, but also throughout the arterial tree (including cerebral arteries).(Level of Evidence: C)" |
References
- ↑ 1.0 1.1 Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwöger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ (November 2014). "2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC)". Eur. Heart J. 35 (41): 2873–926. doi:10.1093/eurheartj/ehu281. PMID 25173340.